

| 化学療法 JNCDB | |
|--------------|------------------------------------------------------------------------------------|
| データベース項目 | 選択肢 |
| 化学療法開始日 | |
| 放射線との併用 | 同時併用ありなし・不明 |
| 手術との併用 | あり(術前)・あり(術後)なし・不明 |
| 薬剤 | 5FUと類似薬・プラチナ製剤・タキサン・その他 |
| プラチナ製剤の投与方法 | 投与なし・20mg/m ² /回未満・40mg/m ² /回未満・40mg/m ² /回以上・不詳 |
| 5FUと類似薬の投与方法 | 投与なし・(持続)静注(5FU)・経口(UFT)・経口(S-1)・その他・不詳 |



| 手術療法・病理所見 JNCDB | |
|-----------------|-----------------------------|
| データベース項目 | 選択肢 |
| 手術施行日 | |
| 手術法 | 食道切除術・バイパス術・試験開胸・その他 |
| リンパ節郭清 | D0・D1・D2・D3・不詳 |
| 根治度 | A, B, C, 不詳 |
| 再建経路 | 胸骨前・胸骨後・後縦隔・その他 |
| 再建臓器 | 胃・空腸・結腸・再建なし・その他 |
| 病期(病理学的) | Stage 0・I・II・III・IVa・IVb・不詳 |
| 総合的癌遺残 | R0, R1, R2, 不詳 |
| 病理学的根治度 | PA・PB・PC・不詳 |

取り扱い規約に準拠し、学会データベースとの共通性を有する

| 放射線療法 JNCDB | |
|--------------|----------------------------------------|
| データベース項目 | 選択肢 |
| 外部照射開始日 | |
| 外部照射終了日 | |
| 術前照射 | ありなし・不詳 |
| 術後照射 | ありなし・不詳 |
| 外部照射の総線量(Gy) | |
| 外部照射回数(回) | |
| スクリューペース | ありなし・不詳 |
| 照射領域 | 縦隔、鎖骨上部～下頸部 |
| 5FUと類似薬の投与方法 | 投与なし(持続)静注(5FU)・経口(UFT)・経口(S-1)・その他・不詳 |

| 治療法選択 | 03-05 | | 99-01 | |
|-------|-------|-----|-------|-----|
| | A1 | B1 | A1 | B1 |
| 手術 | 22% | 19% | 40% | 19% |
| 術前照射 | 15% | 6% | 27% | 11% |
| 術後照射 | 11% | 14% | 23% | 12% |
| 化学療法 | 79% | 74% | 73% | 53% |
| RT単独 | 17% | 22% | 18% | 37% |

99-01とくらべて03-05では化学療法実施率が上昇



放射線治療 PCS & JNCDB



| 施設層 | A1 | | B1 | |
|-----------------------|-------|-------|-------|-------|
| | 03-05 | 99-01 | 03-05 | 99-01 |
| 対象年度 | 03-05 | 99-01 | 03-05 | 99-01 |
| CT-based plan | 87% | 61% | 83% | 70% |
| Multi-Leaf Collimator | 82% | 67% | 76% | 51% |
| 毎回全門照射 | 89% | 73% | 85% | 74% |
| 照射野縮小* | 77% | 83% | 87% | 80% |
| 脊髓線量 > 50Gy | 1% | 4% | 0% | 12% |

*非手術例
放射線治療の実施方法では質的向上が認められる

エネルギー ≥ 6MVの割合 PCS & JNCDB

| | 92-94 | 95-97 | 99-01 | 03-05 |
|----|-------|-------|-------|-------|
| A1 | | 90% | 99% | 100% |
| B1 | - | 76% | 93% | 77% |

03-05のB1施設層の低値については原因調査を要する



腔内照射の実施割合(非手術例) PCS & JNCDB

| | 92-94 | 95-97 | 99-01 | 03-05 |
|----|-------|-------|-------|-------|
| A1 | 29% | 27% | 16% | 14% |
| B1 | 6% | 4% | 3% | 3% |

いずれの施設層でも実施割合は減少を続けている

- まとめ JNCDB
- Quality IndicatorとしてのJNCDB調査項目
- ・ 詳細な情報収集を通し、疾病特有の患者背景を把握
 - ・ 様々な背景因子の相互関係を評価
 - ・ 継続的な情報収集により、疾病構造の変化を評価
 - ・ 学会データベースと比較。疾病のVolume Zoneを知りうる
 - ・ 過去データや国外データと比較し、客観的に評価
 - ・ 病期と集学的治療の適用状況を評価
 - ・ 治療法からみた患者背景を評価
 - ・ 患者群と治療法選択の経時的な変遷を知りうる
 - ・ エビデンスに基づく治療の実施状況を評価

婦人科癌登録の現況

● 患者年報(頸癌・体癌・卵巣癌)
 学会本部で集計
 連結可能匿名化
 UMINインターネットポータルセンター
 がん登録システム
 2005年度集計

| | | |
|-----|-------|-------|
| 頸癌 | 261機関 | 9089例 |
| 体癌 | | 4575例 |
| 卵巣癌 | | 3395例 |

The screenshot shows a complex web interface for data registration. It includes a header with navigation tabs, a main content area with multiple input fields and dropdown menus, and a sidebar with a list of institutions or categories. The interface is designed for detailed data entry and management.

婦人科癌登録委員会 報告

2005年度子宮頸癌登録集計結果

2005年1月1日～12月31日 261機関

対象 1-1 子宮頸癌
 対象 1-2 子宮頸癌
 対象 2 子宮頸癌以外の子宮体癌
 対象 3 子宮頸癌以外の子宮体癌
 対象 4 子宮頸癌以外の子宮体癌
 対象 5 子宮頸癌以外の子宮体癌

2005年度子宮体癌登録集計結果

2005年1月1日～12月31日 261機関

対象 1-1 子宮体癌
 対象 1-2 子宮体癌
 対象 2 子宮体癌以外の子宮体癌
 対象 3 子宮体癌以外の子宮体癌
 対象 4 子宮体癌以外の子宮体癌


2005年度卵巣癌登録集計結果

2005年1月1日～12月31日 261機関

対象 1 卵巣癌
 対象 2 卵巣癌
 対象 3 卵巣癌
 対象 4 卵巣癌
 対象 5 卵巣癌


| 機関名 | 登録例数 | 登録率 | 備考 |
|-----|------|------|----|
| 1 | 1 | 100% | |
| 2 | 2 | 100% | |
| 3 | 3 | 100% | |
| 4 | 4 | 100% | |
| 5 | 5 | 100% | |
| 6 | 6 | 100% | |
| 7 | 7 | 100% | |
| 8 | 8 | 100% | |
| 9 | 9 | 100% | |
| 10 | 10 | 100% | |
| 11 | 11 | 100% | |
| 12 | 12 | 100% | |
| 13 | 13 | 100% | |
| 14 | 14 | 100% | |
| 15 | 15 | 100% | |
| 16 | 16 | 100% | |
| 17 | 17 | 100% | |
| 18 | 18 | 100% | |
| 19 | 19 | 100% | |
| 20 | 20 | 100% | |
| 21 | 21 | 100% | |
| 22 | 22 | 100% | |
| 23 | 23 | 100% | |
| 24 | 24 | 100% | |
| 25 | 25 | 100% | |
| 26 | 26 | 100% | |
| 27 | 27 | 100% | |
| 28 | 28 | 100% | |
| 29 | 29 | 100% | |
| 30 | 30 | 100% | |
| 31 | 31 | 100% | |
| 32 | 32 | 100% | |
| 33 | 33 | 100% | |
| 34 | 34 | 100% | |
| 35 | 35 | 100% | |
| 36 | 36 | 100% | |
| 37 | 37 | 100% | |
| 38 | 38 | 100% | |
| 39 | 39 | 100% | |
| 40 | 40 | 100% | |
| 41 | 41 | 100% | |
| 42 | 42 | 100% | |
| 43 | 43 | 100% | |
| 44 | 44 | 100% | |
| 45 | 45 | 100% | |
| 46 | 46 | 100% | |
| 47 | 47 | 100% | |
| 48 | 48 | 100% | |
| 49 | 49 | 100% | |
| 50 | 50 | 100% | |
| 51 | 51 | 100% | |
| 52 | 52 | 100% | |
| 53 | 53 | 100% | |
| 54 | 54 | 100% | |
| 55 | 55 | 100% | |
| 56 | 56 | 100% | |
| 57 | 57 | 100% | |
| 58 | 58 | 100% | |
| 59 | 59 | 100% | |
| 60 | 60 | 100% | |
| 61 | 61 | 100% | |
| 62 | 62 | 100% | |
| 63 | 63 | 100% | |
| 64 | 64 | 100% | |
| 65 | 65 | 100% | |
| 66 | 66 | 100% | |
| 67 | 67 | 100% | |
| 68 | 68 | 100% | |
| 69 | 69 | 100% | |
| 70 | 70 | 100% | |
| 71 | 71 | 100% | |
| 72 | 72 | 100% | |
| 73 | 73 | 100% | |
| 74 | 74 | 100% | |
| 75 | 75 | 100% | |
| 76 | 76 | 100% | |
| 77 | 77 | 100% | |
| 78 | 78 | 100% | |
| 79 | 79 | 100% | |
| 80 | 80 | 100% | |
| 81 | 81 | 100% | |
| 82 | 82 | 100% | |
| 83 | 83 | 100% | |
| 84 | 84 | 100% | |
| 85 | 85 | 100% | |
| 86 | 86 | 100% | |
| 87 | 87 | 100% | |
| 88 | 88 | 100% | |
| 89 | 89 | 100% | |
| 90 | 90 | 100% | |
| 91 | 91 | 100% | |
| 92 | 92 | 100% | |
| 93 | 93 | 100% | |
| 94 | 94 | 100% | |
| 95 | 95 | 100% | |
| 96 | 96 | 100% | |
| 97 | 97 | 100% | |
| 98 | 98 | 100% | |
| 99 | 99 | 100% | |
| 100 | 100 | 100% | |

| 機関名 | 登録例数 | 登録率 | 備考 |
|-----|------|------|----|
| 1 | 1 | 100% | |
| 2 | 2 | 100% | |
| 3 | 3 | 100% | |
| 4 | 4 | 100% | |
| 5 | 5 | 100% | |
| 6 | 6 | 100% | |
| 7 | 7 | 100% | |
| 8 | 8 | 100% | |
| 9 | 9 | 100% | |
| 10 | 10 | 100% | |
| 11 | 11 | 100% | |
| 12 | 12 | 100% | |
| 13 | 13 | 100% | |
| 14 | 14 | 100% | |
| 15 | 15 | 100% | |
| 16 | 16 | 100% | |
| 17 | 17 | 100% | |
| 18 | 18 | 100% | |
| 19 | 19 | 100% | |
| 20 | 20 | 100% | |
| 21 | 21 | 100% | |
| 22 | 22 | 100% | |
| 23 | 23 | 100% | |
| 24 | 24 | 100% | |
| 25 | 25 | 100% | |
| 26 | 26 | 100% | |
| 27 | 27 | 100% | |
| 28 | 28 | 100% | |
| 29 | 29 | 100% | |
| 30 | 30 | 100% | |
| 31 | 31 | 100% | |
| 32 | 32 | 100% | |
| 33 | 33 | 100% | |
| 34 | 34 | 100% | |
| 35 | 35 | 100% | |
| 36 | 36 | 100% | |
| 37 | 37 | 100% | |
| 38 | 38 | 100% | |
| 39 | 39 | 100% | |
| 40 | 40 | 100% | |
| 41 | 41 | 100% | |
| 42 | 42 | 100% | |
| 43 | 43 | 100% | |
| 44 | 44 | 100% | |
| 45 | 45 | 100% | |
| 46 | 46 | 100% | |
| 47 | 47 | 100% | |
| 48 | 48 | 100% | |
| 49 | 49 | 100% | |
| 50 | 50 | 100% | |
| 51 | 51 | 100% | |
| 52 | 52 | 100% | |
| 53 | 53 | 100% | |
| 54 | 54 | 100% | |
| 55 | 55 | 100% | |
| 56 | 56 | 100% | |
| 57 | 57 | 100% | |
| 58 | 58 | 100% | |
| 59 | 59 | 100% | |
| 60 | 60 | 100% | |
| 61 | 61 | 100% | |
| 62 | 62 | 100% | |
| 63 | 63 | 100% | |
| 64 | 64 | 100% | |
| 65 | 65 | 100% | |
| 66 | 66 | 100% | |
| 67 | 67 | 100% | |
| 68 | 68 | 100% | |
| 69 | 69 | 100% | |
| 70 | 70 | 100% | |
| 71 | 71 | 100% | |
| 72 | 72 | 100% | |
| 73 | 73 | 100% | |
| 74 | 74 | 100% | |
| 75 | 75 | 100% | |
| 76 | 76 | 100% | |
| 77 | 77 | 100% | |
| 78 | 78 | 100% | |
| 79 | 79 | 100% | |
| 80 | 80 | 100% | |
| 81 | 81 | 100% | |
| 82 | 82 | 100% | |
| 83 | 83 | 100% | |
| 84 | 84 | 100% | |
| 85 | 85 | 100% | |
| 86 | 86 | 100% | |
| 87 | 87 | 100% | |
| 88 | 88 | 100% | |
| 89 | 89 | 100% | |
| 90 | 90 | 100% | |
| 91 | 91 | 100% | |
| 92 | 92 | 100% | |
| 93 | 93 | 100% | |
| 94 | 94 | 100% | |
| 95 | 95 | 100% | |
| 96 | 96 | 100% | |
| 97 | 97 | 100% | |
| 98 | 98 | 100% | |
| 99 | 99 | 100% | |
| 100 | 100 | 100% | |



2005年度 総括1. 子宮頸癌治療患者の進行期分布

| 進行期 | 例数 | % | 細分類 | 例数 | % |
|-----|------|------|---------|------|-------|
| 0 | 4239 | 46.6 | 0 | 4239 | 46.6 |
| I | 2578 | 28.4 | I a1 | 659 | 7.7 |
| | | | I a2 | 72 | 0.8 |
| | | | I a12不明 | 78 | 0.9 |
| | | | I b1 | 1258 | 13.8 |
| | | | I b2 | 343 | 3.8 |
| | | | I b12不明 | 65 | 0.7 |
| | | | ab不明 | 63 | 0.7 |
| | | | II a | 318 | 3.5 |
| | | | II b | 827 | 9.1 |
| | | | ab不明 | 2 | 0.0 |
| II | 719 | 7.9 | II a | 45 | 0.5 |
| | | | II b | 671 | 7.4 |
| | | | ab不明 | 3 | 0.0 |
| IV | 406 | 4.5 | IV a | 157 | 1.7 |
| | | | IV b | 236 | 2.6 |
| | | | ab不明 | 13 | 0.1 |
| | | | 合計 | 9089 | 100.0 |



2005年度 子宮頸癌0期治療内容

| 治療法 | 例数 | % |
|------------|------|-------|
| 円錐切除 | 3264 | 77.0 |
| 単純全摘 | 650 | 15.3 |
| 単摘+リンパ節 | 9 | 0.2 |
| 準広汎全摘 | 35 | 0.8 |
| 準広汎全摘+リンパ節 | 12 | 0.3 |
| 広汎全摘 | 4 | 0.1 |
| 放射線療法 | 14 | 0.3 |
| その他 | 239 | 5.6 |
| 合計 | 4239 | 100.0 |

2005年度 子宮頸癌Ia1期治療内容

| 治療法 | 例数 | % |
|------------|-----|-------|
| 円錐切除 | 306 | 49.6 |
| 単純全摘 | 155 | 25.1 |
| 単摘+リンパ節 | 11 | 1.8 |
| 準広汎全摘 | 81 | 13.1 |
| 準広汎全摘+リンパ節 | 44 | 7.1 |
| 広汎全摘 | 12 | 1.9 |
| 放射線療法 | 2 | 0.3 |
| その他 | 6 | 1.0 |
| 合計 | 617 | 100.0 |

2005年度 子宮頸癌Ia2期治療内容


| 治療法 | 例数 | % |
|------------|----|-------|
| 円錐切除 | 5 | 7.5 |
| 単純全摘 | 6 | 9.0 |
| 単摘+リンパ節 | 5 | 7.5 |
| 準広汎全摘 | 9 | 13.4 |
| 準広汎全摘+リンパ節 | 21 | 31.3 |
| 広汎全摘 | 19 | 28.4 |
| 放射線療法 | 0 | 0.0 |
| その他 | 2 | 3.0 |
| 合計 | 67 | 100.0 |

2005年度 子宮頸癌Ia期亜分類不明治療内容

| 治療法 | 例数 | % |
|------------|----|-------|
| 円錐切除 | 11 | 20.4 |
| 単純全摘 | 14 | 25.9 |
| 単摘+リンパ節 | 3 | 5.6 |
| 準広汎全摘 | 8 | 14.8 |
| 準広汎全摘+リンパ節 | 9 | 16.7 |
| 広汎全摘 | 6 | 11.1 |
| 放射線療法 | 2 | 3.7 |
| その他 | 1 | 1.9 |
| 合計 | 54 | 100.0 |


2007年 地区、学医第1-4种施設別

| 地区 | 施設種別 | 手術 | | 放射線 | | 化学療法 | | 合計 | 割合 |
|----|------|------|-----|-----|-----|------|-----|------|------|
| | | 件数 | 割合 | 件数 | 割合 | 件数 | 割合 | | |
| 1 | 総合 | 123 | 1.0 | 5 | 0.2 | 1 | 0.1 | 129 | 1.3 |
| | がん | 123 | 1.0 | 5 | 0.2 | 1 | 0.1 | 129 | 1.3 |
| | がん | 123 | 1.0 | 5 | 0.2 | 1 | 0.1 | 129 | 1.3 |
| | がん | 123 | 1.0 | 5 | 0.2 | 1 | 0.1 | 129 | 1.3 |
| 2 | 総合 | 150 | 1.0 | 10 | 0.3 | 5 | 0.2 | 165 | 1.5 |
| | がん | 150 | 1.0 | 10 | 0.3 | 5 | 0.2 | 165 | 1.5 |
| | がん | 150 | 1.0 | 10 | 0.3 | 5 | 0.2 | 165 | 1.5 |
| | がん | 150 | 1.0 | 10 | 0.3 | 5 | 0.2 | 165 | 1.5 |
| 3 | 総合 | 200 | 1.0 | 15 | 0.4 | 10 | 0.3 | 225 | 2.0 |
| | がん | 200 | 1.0 | 15 | 0.4 | 10 | 0.3 | 225 | 2.0 |
| | がん | 200 | 1.0 | 15 | 0.4 | 10 | 0.3 | 225 | 2.0 |
| | がん | 200 | 1.0 | 15 | 0.4 | 10 | 0.3 | 225 | 2.0 |
| 4 | 総合 | 300 | 1.0 | 25 | 0.6 | 15 | 0.4 | 340 | 3.0 |
| | がん | 300 | 1.0 | 25 | 0.6 | 15 | 0.4 | 340 | 3.0 |
| | がん | 300 | 1.0 | 25 | 0.6 | 15 | 0.4 | 340 | 3.0 |
| | がん | 300 | 1.0 | 25 | 0.6 | 15 | 0.4 | 340 | 3.0 |
| 5 | 総合 | 400 | 1.0 | 35 | 0.8 | 20 | 0.5 | 455 | 4.0 |
| | がん | 400 | 1.0 | 35 | 0.8 | 20 | 0.5 | 455 | 4.0 |
| | がん | 400 | 1.0 | 35 | 0.8 | 20 | 0.5 | 455 | 4.0 |
| | がん | 400 | 1.0 | 35 | 0.8 | 20 | 0.5 | 455 | 4.0 |
| 6 | 総合 | 500 | 1.0 | 45 | 1.0 | 25 | 0.6 | 570 | 5.0 |
| | がん | 500 | 1.0 | 45 | 1.0 | 25 | 0.6 | 570 | 5.0 |
| | がん | 500 | 1.0 | 45 | 1.0 | 25 | 0.6 | 570 | 5.0 |
| | がん | 500 | 1.0 | 45 | 1.0 | 25 | 0.6 | 570 | 5.0 |
| 7 | 総合 | 600 | 1.0 | 55 | 1.2 | 30 | 0.7 | 685 | 6.0 |
| | がん | 600 | 1.0 | 55 | 1.2 | 30 | 0.7 | 685 | 6.0 |
| | がん | 600 | 1.0 | 55 | 1.2 | 30 | 0.7 | 685 | 6.0 |
| | がん | 600 | 1.0 | 55 | 1.2 | 30 | 0.7 | 685 | 6.0 |
| 8 | 総合 | 700 | 1.0 | 65 | 1.4 | 35 | 0.8 | 800 | 7.0 |
| | がん | 700 | 1.0 | 65 | 1.4 | 35 | 0.8 | 800 | 7.0 |
| | がん | 700 | 1.0 | 65 | 1.4 | 35 | 0.8 | 800 | 7.0 |
| | がん | 700 | 1.0 | 65 | 1.4 | 35 | 0.8 | 800 | 7.0 |
| 9 | 総合 | 800 | 1.0 | 75 | 1.6 | 40 | 0.9 | 915 | 8.0 |
| | がん | 800 | 1.0 | 75 | 1.6 | 40 | 0.9 | 915 | 8.0 |
| | がん | 800 | 1.0 | 75 | 1.6 | 40 | 0.9 | 915 | 8.0 |
| | がん | 800 | 1.0 | 75 | 1.6 | 40 | 0.9 | 915 | 8.0 |
| 10 | 総合 | 900 | 1.0 | 85 | 1.8 | 45 | 1.0 | 1030 | 9.0 |
| | がん | 900 | 1.0 | 85 | 1.8 | 45 | 1.0 | 1030 | 9.0 |
| | がん | 900 | 1.0 | 85 | 1.8 | 45 | 1.0 | 1030 | 9.0 |
| | がん | 900 | 1.0 | 85 | 1.8 | 45 | 1.0 | 1030 | 9.0 |
| 11 | 総合 | 1000 | 1.0 | 95 | 2.0 | 50 | 1.1 | 1145 | 10.0 |
| | がん | 1000 | 1.0 | 95 | 2.0 | 50 | 1.1 | 1145 | 10.0 |
| | がん | 1000 | 1.0 | 95 | 2.0 | 50 | 1.1 | 1145 | 10.0 |
| | がん | 1000 | 1.0 | 95 | 2.0 | 50 | 1.1 | 1145 | 10.0 |
| 12 | 総合 | 1100 | 1.0 | 105 | 2.2 | 55 | 1.2 | 1260 | 11.0 |
| | がん | 1100 | 1.0 | 105 | 2.2 | 55 | 1.2 | 1260 | 11.0 |
| | がん | 1100 | 1.0 | 105 | 2.2 | 55 | 1.2 | 1260 | 11.0 |
| | がん | 1100 | 1.0 | 105 | 2.2 | 55 | 1.2 | 1260 | 11.0 |
| 13 | 総合 | 1200 | 1.0 | 115 | 2.4 | 60 | 1.3 | 1375 | 12.0 |
| | がん | 1200 | 1.0 | 115 | 2.4 | 60 | 1.3 | 1375 | 12.0 |
| | がん | 1200 | 1.0 | 115 | 2.4 | 60 | 1.3 | 1375 | 12.0 |
| | がん | 1200 | 1.0 | 115 | 2.4 | 60 | 1.3 | 1375 | 12.0 |
| 14 | 総合 | 1300 | 1.0 | 125 | 2.6 | 65 | 1.4 | 1490 | 13.0 |
| | がん | 1300 | 1.0 | 125 | 2.6 | 65 | 1.4 | 1490 | 13.0 |
| | がん | 1300 | 1.0 | 125 | 2.6 | 65 | 1.4 | 1490 | 13.0 |
| | がん | 1300 | 1.0 | 125 | 2.6 | 65 | 1.4 | 1490 | 13.0 |
| 15 | 総合 | 1400 | 1.0 | 135 | 2.8 | 70 | 1.5 | 1605 | 14.0 |
| | がん | 1400 | 1.0 | 135 | 2.8 | 70 | 1.5 | 1605 | 14.0 |
| | がん | 1400 | 1.0 | 135 | 2.8 | 70 | 1.5 | 1605 | 14.0 |
| | がん | 1400 | 1.0 | 135 | 2.8 | 70 | 1.5 | 1605 | 14.0 |
| 16 | 総合 | 1500 | 1.0 | 145 | 3.0 | 75 | 1.6 | 1720 | 15.0 |
| | がん | 1500 | 1.0 | 145 | 3.0 | 75 | 1.6 | 1720 | 15.0 |
| | がん | 1500 | 1.0 | 145 | 3.0 | 75 | 1.6 | 1720 | 15.0 |
| | がん | 1500 | 1.0 | 145 | 3.0 | 75 | 1.6 | 1720 | 15.0 |
| 17 | 総合 | 1600 | 1.0 | 155 | 3.2 | 80 | 1.7 | 1835 | 16.0 |
| | がん | 1600 | 1.0 | 155 | 3.2 | 80 | 1.7 | 1835 | 16.0 |
| | がん | 1600 | 1.0 | 155 | 3.2 | 80 | 1.7 | 1835 | 16.0 |
| | がん | 1600 | 1.0 | 155 | 3.2 | 80 | 1.7 | 1835 | 16.0 |
| 18 | 総合 | 1700 | 1.0 | 165 | 3.4 | 85 | 1.8 | 1950 | 17.0 |
| | がん | 1700 | 1.0 | 165 | 3.4 | 85 | 1.8 | 1950 | 17.0 |
| | がん | 1700 | 1.0 | 165 | 3.4 | 85 | 1.8 | 1950 | 17.0 |
| | がん | 1700 | 1.0 | 165 | 3.4 | 85 | 1.8 | 1950 | 17.0 |
| 19 | 総合 | 1800 | 1.0 | 175 | 3.6 | 90 | 1.9 | 2065 | 18.0 |
| | がん | 1800 | 1.0 | 175 | 3.6 | 90 | 1.9 | 2065 | 18.0 |
| | がん | 1800 | 1.0 | 175 | 3.6 | 90 | 1.9 | 2065 | 18.0 |
| | がん | 1800 | 1.0 | 175 | 3.6 | 90 | 1.9 | 2065 | 18.0 |
| 20 | 総合 | 1900 | 1.0 | 185 | 3.8 | 95 | 2.0 | 2180 | 19.0 |
| | がん | 1900 | 1.0 | 185 | 3.8 | 95 | 2.0 | 2180 | 19.0 |
| | がん | 1900 | 1.0 | 185 | 3.8 | 95 | 2.0 | 2180 | 19.0 |
| | がん | 1900 | 1.0 | 185 | 3.8 | 95 | 2.0 | 2180 | 19.0 |



**JPCS03-05を含む Quality indicator
: 子宮頸癌**

JNCDB子宮頸癌小作業部会



**JPCSからみたQuality indicator
: Cervix cancer**



- Patient background
- Pretreatment work-up
- Radiotherapy method
- Chemotherapy

**JPCSからみたQuality indicator
: Cervix cancer**



- Patient background
- Pretreatment work-up
- Radiotherapy method
- Chemotherapy

**JPCS Quality indicator: Cervix
Patient background**




- 年齢、病理組織、Stage、PS.....
各年次にて明らかな変化認めず

**JPCSからみたQuality indicator
: Cervix cancer**




- Patient background
- Pretreatment work-up
- Radiotherapy method
- Chemotherapy

**JPCS Quality indicator: Cervix
Pretreatment exam
FIGO permitted/required**



Russel AH et al. ACS. Gynecol Oncol 1996. Amendola MA, et al. ACRIN. JCO 2005.
Toita T et al. Jpn J Clin Oncol in press.

JPCS Quality indicator: Cervix Pretreatment exam FIGO-optimal



Russel AH et al. ACS. Gynecol Oncol 1996. Amendola MA, et al. ACRIN. JCO 2005. Toita T et al. Jpn J Clin Oncol in press.

JPCS Quality indicator: Cervix Pretreatment work-up


- JPCS (JNCDB)により治療前Work-upの質の評価が可能

(現在FIGO分類の改訂作業が進行中)

JPCSからみたQuality indicator : Cervix cancer


- Pretreatment exam
- Radiotherapy method
- Beam energy

JPCS Quality indicator: Cervix Radiotherapy method Beam energy




Toita T et al. Jpn J Clin Oncol 2005. Eifel PJ, et al. IJROBP 2004. Toita T et al. IJROBP in press.

JPCS Quality indicator: Cervix Radiotherapy method Beam energy




Toita T et al. Jpn J Clin Oncol 2005. Eifel PJ, et al. IJROBP 2004. Toita T et al. IJROBP in press.

JPCS Quality indicator: Cervix Radiotherapy method ICBT procedures (ABS recommended)



Toita T et al. IJROBP in press.






JPCS Quality indicator: Cervix Radiotherapy method

- 放射線治療内容の年次変化の評価、日米比較が可能
- ガイドライン(=取扱規約)の遵守状況

JPCSからみたQuality indicator : Cervix cancer

- 放射線治療
- Chemotherapy



**JPCS Quality indicator: Cervix
Chemotherapy**

- CCRTの施行率に関して、年次推移、日米比較が可能



**子宮頸癌
治療ガイドライン**

2007年版
日本婦人科癌学会/編



Q15

1期々日癌に対して根治的放射線療法は実施されるか？

推奨

1期々日癌(子宮頸癌)に対する根治的療法として、根治的放射線療法(放射線療法)が推奨される。根治的放射線療法(放射線療法)は、根治的放射線療法(放射線療法)と併用した根治的放射線療法(放射線療法)が推奨される。

Q17

放射線療法を行う場合、放射線的増進薬と同時化学療法(放射線療法)のいずれが推奨されるか？

推奨

放射線的増進薬とCCRT併用療法(放射線療法)。



**JPCS03-05を含むQuality indicator
: Cervix cancer まとめ**

- JPCSの調査項目は、治療前評価(画像検査)、放射線治療内容、化学療法実施状況等、子宮頸癌の診療内容の観察が可能であり、年次推移・日米比較を行いうるデータを提供する。




Secure System

- ◆ ID and password authentication
- ◆ All data is encrypted
- ◆ Operates only when the Shuttle is connected
- ◆ Impossible to operate a duplicate system
- ◆ Data can be restored via backup data on the admin PC

USB Device (Shuttle)

- ◆ Shuttle stores system and data
- ◆ No installation needed
- ◆ Excellent portability and storability
- ◆ Other PCs can be used for administrative use and data transmission
- ◆ Shuttle is distributed by mail

USB Device Used for the Breast Cancer Registration System



Estimated number of registered cases per year

100 plus cases

USB Hard Drives

70 cases ~ 99 cases

512MB USB Storage Devices


~69 cases

256MB USB Storage Devices

Utilization of the Internet

- ◆ System is automatically updated when connected to the Internet
- ◆ Email is used for data transmission
- ◆ Requests for registration, prognosis surveys, various news, etc., can be sent using simultaneous multiple addressing and selective transmission via email within the center's system

Batch Email Transmission Screen



Input Support (Logic Check)

- ◆ Checks for pages
- ◆ Checks for selected items
- ◆ Checks for data range
- ◆ Inter-item logic check
- ◆ Also checks when batch-loading texts

Data Import/Export

- ◆ Data import and export are available using CSV files
- ◆ When importing data, the number of items, selected items and data range are checked
- ◆ Possible to load data that includes blank items
- ◆ Final checks are performed when data is defined

Survey Texts Batch-loading Screen

| ITEM ID | ITEM NAME | ITEM VALUE |
|---------|-----------|------------|
| ITEM ID | ITEM NAME | ITEM VALUE |
| ITEM ID | ITEM NAME | ITEM VALUE |
| ITEM ID | ITEM NAME | ITEM VALUE |
| ITEM ID | ITEM NAME | ITEM VALUE |
| ITEM ID | ITEM NAME | ITEM VALUE |
| ITEM ID | ITEM NAME | ITEM VALUE |
| ITEM ID | ITEM NAME | ITEM VALUE |
| ITEM ID | ITEM NAME | ITEM VALUE |
| ITEM ID | ITEM NAME | ITEM VALUE |
| ITEM ID | ITEM NAME | ITEM VALUE |


Input Screen 1

Input Screen 2

Input Screen 3

Input Screen 4

Input Screen 5



Registration Results

As of December 9th, 2005
Participating facilities 356 facilities
Estimated number of registered
cases per year 27,952 cases

Number of registered cases in 2004
1,894 cases

Number of registered cases in 2005
177 cases

Operation Issues

- ◆ Internet environments in facilities are heterogeneous
 - Cannot connect to the Internet
 - Cannot use email
 - Cannot connect to the email server directly
 - Transmission from the software through the server is denied
- ◆ Cannot transmit data through hotmail and MSN mail

Future Tasks

- ◆ Continuation of former system's prognosis surveys
- ◆ Introduction of ethical review
- ◆ Expansion of participating facilities by cooperating with local communities

Number of Cases in 2004

(2004.01.01~2004.12.31)

13,879 Cases

Note: The occurrence of breast cancer in both breasts of one patient is calculated as 2 cases.

The Report of
Clinical Statistic Studies on
Registered Breast Cancer Patients
in Japan in 2004

Baseline Characteristics of the Patients: Sex

| Sex | No. of Patients |
|--------------|-----------------|
| Female | 13,825 (99.6%) |
| Male | 54 (0.4%) |
| Total | 13,879 |

Baseline Characteristics of the Patients: Age

| Age | No. of Patients | % |
|--------------|-----------------|------------|
| ~29 | 90 | 0.7 |
| 30~39 | 992 | 7.2 |
| 40~49 | 3,041 | 22.0 |
| 50~59 | 3,938 | 28.5 |
| 60~69 | 3,177 | 23.0 |
| 70~79 | 1,880 | 13.6 |
| 80~ | 689 | 5.0 |
| Unknown | 18 | 0.1 |
| Total | 13,825 | 100 |

Average: 57.2 Median: 56.0

Baseline Characteristics of the Patients: Family History of Breast Cancer

| Family History | No. of Patients | % |
|----------------|-----------------|--------------|
| No | 11,991 | 86.7 |
| Yes | 1,129 | 8.2 |
| Unknown | 705 | 5.1 |
| Total | 13,825 | 100.0 |

Baseline Characteristics of the Patients: Menopause Status

| Menopause | No. of Patients | % |
|--------------|-----------------|--------------|
| Pre | 4,706 | 34.0 |
| Post | 8,702 | 62.9 |
| Unknown | 417 | 3.0 |
| Total | 13,825 | 100.0 |

Methods of the Detection

| Methods | No. of Patients | % |
|-------------------------------------------------|-----------------|--------------|
| Self-Detection | 10,141 | 73.4 |
| Health Examination (with Subjective Symptom) | 779 | 5.6 |
| Health Examination (without Subjective Symptom) | 2,085 | 15.1 |
| Other | 683 | 4.9 |
| Unknown | 137 | 1.0 |
| Total | 13,825 | 100.0 |

Tumor Size

| Tumor Size (cm) | No. of Patients | % |
|-----------------|-----------------|--------------|
| 0 | 447 | 3.2 |
| ~0.5 | 132 | 1.0 |
| 0.6~1.0 | 1,254 | 9.1 |
| 1.1~2.0 | 4,449 | 32.2 |
| 2.1~5.0 | 5,880 | 42.5 |
| 5.1~10.0 | 947 | 6.9 |
| 10.1~ | 142 | 1.0 |
| Unknown | 574 | 4.2 |
| Total | 13,825 | 100.0 |

Primary Tumor (T)

| T | No. of Patients | % |
|----------------|-----------------|--------------|
| T0 | 204 | 1.5 |
| T1 | 5,250 | 38.0 |
| T2 (2.1~3.0cm) | 3,255 | 23.5 |
| T2 (3.1~5.0cm) | 2,023 | 14.6 |
| T3 | 666 | 4.8 |
| T4a | 78 | 0.6 |
| T4b | 569 | 4.1 |
| T4d | 119 | 0.9 |
| Tis | 1,018 | 7.4 |
| Unknown | 643 | 4.7 |
| Total | 13,825 | 100.0 |

Regional Lymph Nodes (N)

| N | No. of Patients | % |
|--------------|-----------------|--------------|
| N0 | 10,709 | 77.5 |
| N1 | 2,451 | 17.7 |
| N2 | 444 | 3.2 |
| N3 | 113 | 0.8 |
| Unknown | 108 | 0.8 |
| Total | 13,825 | 100.0 |

Distant Metastasis (M)

| M | No. of Patients | % |
|--------------|-----------------|--------------|
| M0 | 13,217 | 95.6 |
| M1 | 367 | 2.7 |
| Unknown | 241 | 1.7 |
| Total | 13,825 | 100.0 |

Stages

| Stages | No. of Patients | % |
|--------------|-----------------|--------------|
| 0 | 963 | 7.0 |
| I | 4,671 | 33.8 |
| IIa | 4,090 | 29.6 |
| IIb | 1,538 | 11.1 |
| IIIa | 487 | 3.5 |
| IIIb | 562 | 4.1 |
| IIIc | 66 | 0.5 |
| IV | 367 | 2.7 |
| Unknown | 1,081 | 7.8 |
| Total | 13,825 | 100.0 |

Adjuvant Therapy and Surgery

| Adjuvant Therapy | Preoperative | Postoperative | Nonoperative |
|------------------|----------------------------|----------------------------|---------------------|
| No | 12,537 (91.8%) | 2,226 (16.3%) | 0 |
| Yes | 1,112 (8.1%) | 11,361 (83.2%) | 171 (100.0%) |
| Unknown | 5 (0.0%) | 67 (0.5%) | 0 |
| Total (%) | 13,654 (100.0%) | 13,654 (100.0%) | 171 (100.0%) |

Types of Adjuvant Therapy and Surgery

| Types | Preoperative | Postoperative | Nonoperative |
|---------------------------------------|---------------------------|----------------------------|---------------------|
| Chemotherapy | 1,015 (91.3%) | 5,557 (48.9%) | 127 (74.3%) |
| Endocrinotherapy | 184 (16.5%) | 9,146 (80.5%) | 88 (51.5%) |
| Molecular Target/ Antibody Therapy | 0 (0.0%) | 114 (1.0%) | 0 (0.0%) |
| Radiotherapy | 22 (2.0%) | 4,758 (41.9%) | 29 (17.0%) |
| Other | 8 (0.7%) | 21 (0.2%) | 5 (2.9%) |
| No. of Cases | 1,112 (100.0%) | 11,361 (100.0%) | 171 (100.0%) |

Regions of Postoperative Irradiation

| Regions | No. of Patients | % |
|----------------------|-----------------|--------------|
| Breast | 4,899 | 90.2 |
| Regional Lymph Nodes | 620 | 11.4 |
| Chest Wall | 439 | 8.1 |
| Other | 36 | 0.7 |
| No. of Cases | 5,434 | 100.0 |

Surgical Techniques and Postoperative Irradiation

| Surgical Techniques | Irradiation | | | Total |
|-------------------------------------------------------------------|--------------|--------------|-----------|---------------|
| | No | Yes | Unknown | |
| None | 7 | 5 | 0 | 12 |
| Breast Conserving Surgery | 1,955 | 4,870 | 25 | 6,850 |
| Total Mastectomy Mastectomy with Conservation of Pectoral Muscles | 729 | 25 | 3 | 757 |
| Radical Mastectomy | 5,315 | 486 | 11 | 5,812 |
| Other | 60 | 19 | 0 | 79 |
| Unknown | 112 | 30 | 0 | 142 |
| Unknown | 1 | 0 | 1 | 2 |
| Total | 8,179 | 5,435 | 40 | 13,654 |

Surgical Techniques and Region of Postoperative Irradiation

| Surgical Techniques | Region | | | | No. of Cases |
|-------------------------------------------------------------------|--------------|----------------------|------------|-----------|--------------|
| | Breast | Regional Lymph Nodes | Chest Wall | Other | |
| None | 5 | 0 | 0 | 0 | 5 |
| Breast Conserving Surgery | 4,804 | 284 | 89 | 12 | 4,870 |
| Total Mastectomy Mastectomy with Conservation of Pectoral Muscles | 7 | 11 | 10 | 1 | 25 |
| Radical Mastectomy | 54 | 312 | 325 | 20 | 485 |
| Other | 3 | 10 | 12 | 3 | 19 |
| Unknown | 26 | 3 | 3 | 0 | 30 |
| Total | 4,899 | 620 | 439 | 36 | 5,434 |

Axillary Node Dissections

| Types of Dissection | No. of Patients | % |
|---------------------|-----------------|--------------|
| None | 1,002 | 7.3 |
| ALND | 9,572 | 69.2 |
| SLNB | 2,571 | 18.6 |
| Sampling | 281 | 2.0 |
| Other | 215 | 1.6 |
| Unknown | 184 | 1.3 |
| Total | 13,825 | 100.0 |

Axillary Lymph Node Dissection: ALND
Sentinel Lymph Node Biopsy: SLNB

ER Status

| ER | No. of Patients | % |
|-------------------------|-----------------|--------------|
| + | 9,903 | 71.6 |
| - | 3,383 | 24.5 |
| Unknown or Not Measured | 539 | 3.9 |
| Total | 13,825 | 100.0 |

PgR Status

| PgR | No. of Patients | % |
|-------------------------|-----------------|--------------|
| + | 8,158 | 59.0 |
| - | 5,084 | 36.8 |
| Unknown or Not Measured | 583 | 4.2 |
| Total | 13,825 | 100.0 |

Her2 Status

| Her2 | No. of Patients | % |
|-------------------------|-----------------|--------------|
| + | 1,684 | 12.2 |
| - | 9,217 | 66.7 |
| Unknown or Not Measured | 2,924 | 21.2 |
| Total | 13,825 | 100.0 |

Surgical Techniques


| Technique | No. of Patients | % |
|----------------------|-----------------|--------------|
| None | 12 | 0.1 |
| BCS | 6,850 | 49.6 |
| Simple Mastectomy | 757 | 5.5 |
| Mastectomy with ALND | 5,812 | 42.0 |
| Radical Mastectomy | 79 | 0.6 |
| Other | 142 | 1.0 |
| Unknown | 173 | 1.3 |
| Total | 13,825 | 100.0 |

Breast Conserving Surgery: BCS


Histological Type

| Types of Tissue | No. | % | Types of Tissue | No. | % |
|--------------------------------------------------------|--------|------|-------------------------|---------------|--------------|
| Noninvasive Ductal Carcinoma | 1,143 | 8.3 | Paget's Disease | | |
| Lobular Carcinoma In Situ | 47 | 0.3 | Noninvasive | 37 | 0.3 |
| Invasive Ductal Carcinoma | 11,001 | 78.8 | Invasive | 9 | 0.1 |
| | | | Sarcoma | | |
| Special Types | | | Cystosarcoma Phylloides | 20 | 0.1 |
| Mucinous Carcinoma | 473 | 3.4 | Carcinosarcoma | 1 | 0.0 |
| Intraductal Carcinoma | 113 | 0.8 | Stromal Sarcoma | 3 | 0.0 |
| Invasive Lobular Carcinoma | 444 | 3.2 | Lymphosarcoma | 10 | 0.1 |
| Adenoid Cystic Carcinoma | 14 | 0.1 | Other | 2 | 0.0 |
| Squamous Cell Carcinoma | 28 | 0.2 | Unknown | 158 | 1.1 |
| Spindle Cell Carcinoma | 18 | 0.1 | Total | 13,825 | 100.0 |
| Apocrine Carcinoma | 152 | 1.1 | | | |
| Carcinoma with Cartilaginous and/or Osseous Metaplasia | 9 | 0.1 | | | |
| Tubular Carcinoma | 39 | 0.3 | | | |
| Secretory Carcinoma (Juvenile Carcinoma) | 9 | 0.1 | | | |
| Other | 88 | 0.7 | | | |


5-Year Survival Rate (In 1997)




5-Year Survival Rate by Stages (In 1997)



10-Year Survival Rate (In 1992)



10-Year Survival Rate by Stages (In 1992)




Facility-Specific Benchmark Reports in the Japanese Breast Cancer Society Breast Cancer Registration System

- Generates sample reports
 - Data for your own program
 - Aggregate data
 - Data from your own program compared to aggregate


Selected Breast Cancer Measures

- ◆ BRT- Patients receiving breast conserving surgery who are under age 70 should receive or be considered for radiation therapy.

BRT




BRT




Selected Breast Cancer Measures

- ◆ MAC- Patients with Stage I (tumor size > 1cm and N+) or Stage II/III (any tumor size and N+), with ER/PR – tumors should receive or be considered for combination chemotherapy.

MAC




MAC




Selected Breast Cancer Measures

- ◆HT- Patients with Stage I (tumor size >1cm and N+) or Stage II/III (any tumor size and N+), with ER+ or PR + tumors should receive or be considered for hormone chemotherapy (Tamoxifen or third generation Aromatase Inhibitor).

HT



HT



Results

- ◆Our system can provides cancer program specific estimated performance rates for clinical process measures for breast cancer to participating facilities.


乳癌における JPCS03-05を含むquality indicator

日本PCS乳癌小作業部会
山内 智香子, 光森 通英


Quality Indicator: 診療の質指標

- 患者のために良いと医学上知られていることがきちんと行われているか
- 質指標となる診療: 最先端医療や個別対応の診療ではなく常に行うべき標準的診療 (しっかりとしたエビデンスまたは専門家の合意がある)


乳癌術後照射に関する ガイドラインとPCS



PMRT(照射部位)



病理報告書の有無



全乳房照射: 固定具の使用率

